In conclusion, we report here the potent anti-tumor activity for the blockade of Dll4 as monotherapy and a benefit for the combined treatment of anti-Dll4 with VEGF pathway targeting agents in ccRCC PDX models. This evidence concerns the gene DLL4 and nonpapillary renal cell carcinoma.